Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …

Conclusions Despite clear relationships between HBV RNA and HBcrAg levels and CHB
phases, these markers have limited additional value in differentiating CHB phases because …

At least 25 bioactive glass (BG) medical devices have been approved for clinical use by
global regulatory agencies. Diverse applications include monolithic implants, bone void …

The major risk factors for hepatocellular carcinoma (HCC) in contemporary clinical practice
are becoming increasingly related to sustained virological response after hepatitis C …

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its
mortality is third among all solid tumors, behind carcinomas of the lung and the colon …

Purpose In light of recently published clinical reports and trials, the TheraSphere Global
Dosimetry Steering Committee (DSC) reconvened to review new data and to update …

Hepatocellular carcinoma (HCC) is the third most common cause of cancer‐related death
and occurs mainly in the context of chronic liver disease at cirrhosis stage. The Barcelona …

Embolization with microspheres is a therapeutic strategy based on the selective occlusion of
the blood vessels feeding a tumor. This procedure is intraarterially performed in the clinical …

Purpose To study the correlation between absorbed perfused liver dose using Y90
radioembolization and degree of hepatocellular carcinoma (HCC) necrosis in liver explants …